# GLP-1 Medications Transform Weight Loss Market as Safety Concerns Emerge

# SEO-Friendly Podcast Episode Description## Navigating Ozempic: FDA Approves First GLP-1 Weight Loss Pill - Foundayo vs. Wegovy Battle BeginsDiscover the latest breakthrough in weight loss medications as the FDA approves **Eli Lilly's Foundayo** (orforglipron), the first oral GLP-1 pill for obesity treatment. This episode of Navigating Ozempic covers the groundbreaking approval that's reshaping the $100 billion metabolic health market.**What You'll Learn:**- **Foundayo approval details**: The first daily pill alternative to weekly Ozempic and Wegovy injections- **Clinical results**: 12.4% average weight loss over 72 weeks- **Affordable pricing**: As low as $25/month with insurance, $149 self-pay- **Market competition**: Eli Lilly vs. Novo Nordisk in the GLP-1 obesity drug wars- **Important safety updates**: Latest FDA warnings on gastroparesis, kidney injury, and pancreatitis- **Lawsuit information**: 2,914 active cases against GLP-1 manufacturers- **Good news**: FDA removes suicidal ideation warnings after comprehensive review- **Women's health concerns**: Muscle loss risks and metabolic implications- **Cardiovascular benefits**: New Health Canada approval for heart disease protection**Keywords**: Ozempic, Foundayo, orforglipron, Wegovy, GLP-1 medications, weight loss pills, semaglutide, obesity treatment, metabolic health, FDA approval, Eli Lilly, Novo NordiskPerfect for anyone considering GLP-1 medications, healthcare professionals, or those tracking pharmaceutical industry developments.*A Quiet Please Production*Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AIThis episode includes AI-generated content.